Clinical trial
Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV…
NCT00140244 · Beth Israel Deaconess Medical Center, Other · Completed
Key facts
| NCT number | NCT00140244 |
|---|---|
| Title | Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome |
| Official title | Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients |
| Lead sponsor | Beth Israel Deaconess Medical Center, Other |
| Collaborators | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH Amgen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HAART-induced Lipodystrophy and Metabolic Syndrome |
| Intervention type | Drug |
| Interventions | r-metHuLeptin, Placebo |
| Enrollment | 7 |
| Start date | Dec 1, 2001 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Sep 1, 2005 |
| Last update posted | May 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: